FMI Retinoblastoma Treatment Market Opportunities, Dem | Page 4

Retinoblastoma Treatment Market
Retinoblastoma Treatment Market Latest Trends, Demand and Analysis 2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated
by World Health Organization (WHO). Retinoblastoma is a cancer that starts in the retina, the very back
part of the eye. It is the most common type of eye cancer in children. During the early stages of
development, the eyes have cells called retinoblasts that divide into new cells and fill the retina. At a
certain point, these cells stop dividing and develop into mature retinal cells. Rarely, something goes
wrong with this process. Instead of maturing into special cells that detect light, some retinoblasts
continue to divide and grow out of control, forming a cancer known as retinoblastoma. Retinoblastoma
starts with a mutation in a gene called the retinoblastoma (RB1) gene. Depending upon the changes in
RB1 gene, retinoblastomas are two types, they are congenital (hereditary) retinoblastoma and sporadic
(non-hereditary) retinoblastoma. Retinoblastoma is a rare disease. 9 in 10 children suffering from
retinoblastoma are cured with the existing treatments.
Request Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-2783
Retinoblastoma Treatment Market: Drivers and Restraints
Retinoblastoma treatment market is driven by increasing remissions or recurrence of the disease and
increasing awareness among healthcare professionals and patients. According to American Cancer
Society, Inc. there are only about 200 to 300 children are diagnosed with retinoblastoma each year in the
United States. Apart from aforementioned drivers, retinoblastoma market is driven by availability of
©2015 Future Market Insights, All Rights Reserved
4